创新药独立行情贯穿全年，左侧板块下半年有望反转

Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs, with expectations of a recovery in performance in the second half of 2025 [1][5]. Core Insights - The pharmaceutical sector is under pressure in 2024 and Q1 2025 due to factors such as healthcare payment environment, industry regulation, and changing consumer conditions, but a recovery is anticipated in the latter half of 2025 [1][18]. - The innovative drug segment is highlighted as a key investment focus, with strong revenue growth and business development (BD) performance from leading companies [2][22]. - The report emphasizes the potential for significant growth in the biopharmaceutical sector, particularly in oncology and chronic disease treatments, supported by clinical advancements and market expectations [2][28]. Summary by Sections Pharmaceutical Sector Overview - The overall performance of the pharmaceutical sector is expected to remain under pressure in 2024 and Q1 2025, with a gradual recovery anticipated in the second half of 2025 as market pressures ease [1][18]. - The innovative drug segment is performing well, with leading companies experiencing revenue growth and successful BD activities [2][22]. Innovative Drugs - Leading innovative drug companies are seeing a continuous increase in revenue and BD income, with strong expectations for growth in oncology and chronic disease markets [2][22]. - The report identifies key players such as BeiGene and Hengrui Medicine as having strong growth trajectories [22]. Biopharmaceuticals - The biopharmaceutical sector is expected to show robust growth, with a focus on long-acting interferons and insulin products, despite some challenges in pricing and market conditions [2][4]. - The report notes that the innovative drug segment has maintained a growth rate of over 20% for two consecutive years, indicating a strong market position [28]. Retail Pharmacy - The retail pharmacy sector is showing signs of marginal improvement, with expectations of a return to normal growth in 2025 [2][4]. - The report highlights the impact of policy changes and market conditions on retail pharmacy performance, with some companies experiencing declines in non-pharmaceutical sales [2][4]. Medical Services and Aesthetic Medicine - The medical services and aesthetic medicine sectors are expected to see moderate recovery, with leading brands maintaining strong performance despite external pressures [3][4]. - The report anticipates that the demand for medical services will remain stable, supporting growth for leading companies in the sector [3]. Traditional Chinese Medicine - The traditional Chinese medicine sector is expected to improve gradually after facing challenges in 2024, with a focus on inventory digestion and channel reform [4][12]. - The report suggests that the sector may experience a growth pattern of "low first, high later" throughout the year [4]. Medical Devices - The medical device sector is projected to recover gradually, with significant growth opportunities in overseas markets [4][12]. - The report notes that domestic demand remains weak, but international expansion is becoming a key growth driver for many companies [4].